Laimei Pharmaceutical Co., Ltd. was founded in Chongqing in 1999 and headquartered in Chongqing. After more than ten years to forge ahead, growth is a research, production and sales of high-tech pharmaceutical enterprise. October 2009, the company was listed on Shenzhen Stock Exchange GEM stock code 300 006. The total assets of 880 million yuan, registered capital of 91.5 million yuan, more than 750 employees. The company mainly produces specialty anti-infectives and specialty drugs, the main products quinolone class of anti-infectives, anti-tumor drugs, parenteral nutrition, medicine, etc., in 2009 sales revenue reached 370 million.

2007 annual Grammy was awarded the first" Chongqing High-tech top ten technology innovation ", and in 08, 09 years in a row this award. Company logo "Grammy" was identified as "Chongqing famous trademark", a number of varieties were rated as "high-tech products in Chongqing", "Chongqing key new products", "Chongqing Famous Brand", "Chongqing well-known products" and has been awarded "Advanced Enterprise in Chongqing tax credit."

Grammy great importance to R & D investment. Companies adhering to the concept of research as a leader, since its establishment has invested nearly billion for research and development. R & D strength, with "Lay America Pharmaceutical Technology Center of Chongqing," "Grammy - Sichuan University, Joint Laboratory" two R & D platform, which, "Lay America Pharmaceutical Technology Center of Chongqing," was named the Chongqing municipal enterprises Technology Center. R & D team of professional and experienced, with the introduction from abroad of professional and technical personnel 116 people, including home, PhD, MS, etc. In drug design, screening, pre-clinical research, clinical research, the integrity of our system, self-contained. After 10 years of development, research and innovation in the formation of the lymphatic tracer, lymphatic targeting chemotherapy and targeted cancer chemotherapy nanomedicine technology as the representative of the independent R & D platform to micro, nano-dispersion technology and the preparation of sterile bulk drugs technology as the representative of the research into technology platform, and to anti-infective drugs and characteristics of specialty drugs, represented by generic platform. The company has applied for 15 patents in China.

Grammy is the earliest GMP, GSP certification companies. New and longevity in tea production base of chemical industry park has 85,000 square meters. Production of various types of finished products and 40 species, of which 28 species are listed as national "health insurance directory", representing all 70 species of finished products. In the manufacturing process, technology and equipment, the Grammy currently available the leading domestic level miscible injection (injection with freeze-dried suspension) and sterile bulk drugs and other preparation techniques, which have been the first injection of freeze-dried suspension of domestic market . Products stocked, has made 86 drug registration orders, covering a large capacity, small volume injection, powder and freeze-dried powder injection, including all dosage forms, is the most complete injection dosage form pharmaceutical companies. Adhering to the concept of quality of life, promote the company's overall management of cGMP, a number of products is higher than the national standard of internal control standards, product quality and long-term market sampling 100%pass rate, access to broad user acceptance and trust.

Grammy continue to open up the market, the company's wholly owned subsidiary of Grammy Pharmaceutical Co., Ltd. is a professional pharmaceutical sales company marketing network covers 29 provinces, municipalities, has been in Beijing, Shanghai, Guangzhou, Chengdu, Xinjiang has established 25 offices across the country with excellent customer resources and marketing network resources.

Lay the United States will continue to receive" Quality is life, innovation is the driving force, the customer is the enterprise's resources "business philosophy to" pragmatic innovation, people-oriented, committed to medicine, creating a healthy "for business purposes in an effort to build the company into line with international cGMP standards and national GMP, GSP standards, R & D strength, advanced production technology and management, sales team competitive, good reputation, product market share rather share of the domestic first-class medical R & D and manufacturing, continue to create value for shareholders, for the continuous improvement of human health!